Therapeutic Targeting of RAS Mutant Cancers
Book Details
Format
Paperback / Softback
Book Series
Elements in Molecular Oncology
ISBN-10
1009073648
ISBN-13
9781009073646
Publisher
Cambridge University Press
Imprint
Cambridge University Press
Country of Manufacture
GB
Country of Publication
GB
Publication Date
Sep 15th, 2022
Print length
75 Pages
Weight
78 grams
Dimensions
15.10 x 22.90 x 0.80 cms
Product Classification:
OncologyPathologyPharmacology
Ksh 3,250.00
Manufactured on Demand
Delivery in 29 days
Delivery Location
Delivery fee: Select location
Delivery in 29 days
Secure
Quality
Fast
The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations.
The KRAS oncogene is believed to be the most common single nucleotide variant oncogene in human cancer. Historically, efforts to target KRAS and the other RAS GTPases have struggled. More recently, efforts have focused on identifying and exploiting features unique to specific oncogenic mutations. This has led to the first FDA approval for a RAS targeted therapy. This new agent is a covalent inhibitor that reacts with the cysteine residue created by a codon 12 glycine to cysteine (G12C) mutation within KRAS. Mutant-specific strategies may also exist for other KRAS single nucleotide variants, and recent studies provide examples and mechanisms.
Get Therapeutic Targeting of RAS Mutant Cancers by at the best price and quality guaranteed only at Werezi Africa's largest book ecommerce store. The book was published by Cambridge University Press and it has pages.
